Ionis Pharmaceuticals (IONS) and Biogen (BIIB) Report Updates on tofersen Phase 3 VALOR study in SOD1-ALS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Ionis Pharmaceuticals (IONS) and Biogen (BIIB) Report Updates on tofersen Phase 3 VALOR study in SOD1-ALS

Ionis Pharmaceuticals (IONS) PT Lowered to $68 at Laidlaw

October 18, 2021 7:53 AM EDT

Laidlaw analyst Yale Jen lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $78.00) while maintaining a Buy rating.

Tofersen in SOD1-ALS VALOR Trial Failed to Meet Primary Endpoint but Substantial Knowledge Learned... More